The biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent years.
When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. This has earned the industry a lot of respect.
Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s most influential people. From expert views on biomarkers and interventions, the definition of biological age, the secret to healthy aging, or AI and COVID-19, we’ve put together some of our favourites.
About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue.
Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr. John Dimos is making the most of it.
On this week’s Tech Nation, Moira speaks with Dr. Thomas Rando, Co-Founder of Fountain Therapeutics, a Professor at Stanford University School of Medicine and Director of Glen Laboratories on the Biology of Aging, about a rampant medical condition – aging.
Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company. The company joins a select group of emerging biotech companies spearheading innovation in drug …
As Healthy Aging Month arrives, Dr Thomas Rando shares his views on progress in Longevity science. For the past two decades, September has been celebrated as Healthy Aging Month in the United States – an annual period of health observance focused on aging and better health practices.
John Dimos, CEO, Fountain Therapeutics describes their approach to the treatment of age-associated diseases and points out that there is a big difference between chronological and biological age.
To see the affects of aging all you have to do is look in a mirror and watch the changes over time. Fountain Therapeutics is training its artificial intelligence platform to look at individual cells to detect changes that occur as cells get older and discover therapeutics that target underlying mechanisms of aging.